Zusammenfassung
Derzeit existiert keine nationale Leitlinie für die Diagnostik, Therapie und Nachsorge des Ösophaguskarzinoms. Das Erscheinen einer solchen Leitlinie ist für 2015 geplant (http://www.awmf.org/leitlinien/detail/anmeldung/1/ll/021-023OL.html).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Abnet CC et al.(2009) Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 100(3): 551 557
Ajani JA et al. (2011) Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw. 9(8): 830–887
Allum WH et al. (2009) Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol, 27(30): 5062–5067
Amenabar A., Hoppo T, Jobe BA (2013) Surgical management of gastroesophageal junction tumors. Semin Radiat Oncol, 23(1): 16–23
Ancon, E et al. (2008) Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol. 15(11): 3278–88
Anderson LL, Lad TE (1982) Autopsy findings in squamous-cell carcinoma of the esophagus. Cancer 50(8): 1587–1590
Arnott SJ et al. (2005) Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev (4): CD001799.
Atkins BZ et al. (2004) Reducing hospital morbidity and mortality following esophagectomy. Ann Thorac Surg. 78(4): 1170–1176
Bang YJ et al. (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379(9813): 315–321
Bang YJ et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376(9742):687–697
Barzi A, Lenz HJ (2012) Angiogenesis-related agents in esophageal cancer. Expert Opin Biol Ther. 12(10): 1335–1345
Baumhoer D, Ramadori G (2005) Ösophaguskarzinome - aktueller Stand der Diagnostik und Therapie. Z Gastroenterol 43(4): 399–409
Beatty JD, DeBoer G,. Rider WD (1979) Carcinoma of the esophagus: pretreatment assessment, correlation of radiation treatment parameters with survival, and identification and management of radiation treatment failure. Cancer. 43(6): 2254–2267
Bedard ELet al. (2001) The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer. 91(12): 2423–2430
Bedenne, L et al. (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 25(10): 1160–1168
Bennett C et al. (2012) Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 143(2): 336–346
Biere SS et al. (2012) Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 379(9829):1887–1892
Birkmeyer JD et al. (2002) Hospital volume and surgical mortality in the United States. N Engl J Med. 346(15): 1128–1137
Birkmeyer JD et al. (2003) Surgeon volume and operative mortality in the United States. N Engl J Med. 349(22): 2117–2127
Bleiberg H et al. (1997) Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 33(8): 1216–1220
Bollschweiler E, Holscher AH (2007) Prognosis of early esophageal cancer: differences between squamous cell carcinoma and adenocarcinoma. Ann Surg. 245(2): 334
Borchard, F (1985) Epidemiologie, Ätiologie und pathologische Anatomie des Ösophaguskarzinoms. in: Denck H, Paquet KJ, Zöckler CE (Hrsg.). Chirurgische Gastroenterologie mit interdisziplinären Gesprächen, TM Verlag, Hameln. Nr. 2(8/85): 7–15
Bosset, JF et al. (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 337(3): 161–167
Brown, LM, Devesa SS, Chow WH (2008) Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 100(16): 1184–1187
Buas MF, Vaughan TL (2013) Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol. 23(1): 3–9
Buergy, D et al. (2012) Radiotherapy for tumors of the stomach and gastroesophageal junction–a review of its role in multimodal therapy. Radiat Oncol. 7: 192
Burmeister, BH et al. (2011) A randomized phase II trial of two regimens of moderate dose chemoradiation therapy for patients with non-small cell lung cancer not suitable for curative therapy: Trans Tasman Radiation Oncology Study TROG 03.07. J Thorac Oncol. 6(12): p. 2076–2082
zum Buschenfelde CM et al. (2011) (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med. 52(8): 1189–1196
Bystricky B, Okines AF, Cunningham D (2011) Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 71(5): p. 541–555
Caspers RJ et al. (1993) Combined external beam and low dose rate intraluminal radiotherapy in oesophageal cancer. Radiother Oncol. 27(1): 7–12
Chakravarty T et al. (2010) Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. Int J Radiat Oncol Biol Phys. 83(2): 581–586
Conroy T et al. (1996) Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol. 14(1): 164–170
Cooper JS et al. (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 281(17): 1623–1627
Cooper SC et al. (2010) The risk of oesophageal cancer is not affected by a diagnosis of breast cancer. Eur J Cancer Prev, 2010. 19(3): p. 182–185
Corley A, Kubo A, Zhao W (2008) Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev. 17(2): 352–358
Cunningham D et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006. 355(1): 11–20
Cunningham E (2006) What is the registered dietitian’s role in the preoperative assessment of a client contemplating bariatric surgery? J Am Diet Assoc, 2006. 106(1): 163
Dantoc M, Cox MR, Eslick GD (2012) Evidence to support the use of minimally invasive esophagectomy for esophageal cancer: a meta-analysis. Arch Surg. 147(8): 768–776
Das A et al. (2006) Association of esophageal adenocarcinoma with other subsequent primary cancers. J Clin Gastroenterol. 40(5): 405–411
Das D, Chilton AP, Jankowski JA, (2009) Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 181: 161–169
Dikken JL et al. (2013) Differences in outcomes of oesophageal and gastric cancer surgery across Europe. Br J Surg. 100(1): 83–94
Dikken JL et al. (2012) Influence of hospital type on outcomes after oesophageal and gastric cancer surgery. Br J Surg. 99(7): 954–963
Dikke JL et al. (2011) Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 11: 32.
Djarv T, Lagergren P (2012) Quality of life after esophagectomy for cancer. Expert Rev Gastroenterol Hepatol. 6(1): 15–22
Emami B et al. (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 21(1):109–122
Engel LS et al. (2003) Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 95(18): 1404–1413
Erickson LA (2005) Sternberg’s Diagnostic Surgical Pathology, 4th ed. The American Journal of Surgical Pathology. 29(3): 425
Fakhrian K et al. (2013) Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk : Planning study in esophageal carcinoma. Strahlenther Onkol. 189(4): p. 293–300
Fiorica F et al. (2004) Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut, 53(7): p. 925–930
Flamen P et al. (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol, 2000. 18(18): 3202–1320
Freedman ND et al. (2007) A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol. 165(12):1424–1433
Freedman ND et al. (2011) Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut. 60(8): 1029–1037
Fritz P, Wannenmacher M (1997) Radiotherapy in the multimodal treatment of esophageal carcinoma. A review. Strahlenther Onkol. 173(6): 295–308
Fritz P et al. (2003) Concurrent chemotherapy and radiation therapy for unresectable locally advanced carcinoma of the esophagus. Phase II study and clinical review on literature. Strahlenther Onkol. 179(5): 328–36
Fujiwara Y et al. (2012) Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients. Oncol Rep. 28(2): 446–452
Gebski V et al. (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol, 2007. 8(3): 226–234
de Geus-Oei, LF et al. (2012) FDG-PET/CT based response-adapted treatment. Cancer Imaging. 12(2): 324–335
Gignoux M et al. (1987) The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World J Surg. 11(4): 426–432
Greenwald BD et al. (2010) Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. Gastrointest Endosc. 71(4): 686–693
van Hagen P et al. (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 366(22): 2074–2084
Haneder S et al. (2012) Assessment of renal function after conformal radiotherapy and intensity modulated radiotherapy by functional 1H-MR-imaging and 23Na-MR-imaging. Strahlenther Onkol Dec; 188 (12): 1146–1154
Hardikar S et al. (2013) The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett’s esophagus. PLoS One. 8(1): p. e52192
Hasegawa S et al. (2013) Esophagus or stomach? The seventh TNM classification for Siewert type II/III junctional adenocarcinoma. Ann Surg Oncol. 20(3): 773–779
Herskovic A et al. (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med, 1992. 326(24): 1593–1598
Holscher, A.H et al. Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. Ann Surg. 254(5): p. 802–7; discussion 807–8.
Homs MY (2004) et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet. 364(9444): 1497–1504
Hsu FM et al. (2011) Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 81(4): e593–599
Huber K. (2013) Karzinom des Ösophagus und des gastroösophagealen Übergangs. Strahlentherapie und Onkologie February, Volume 189, ”/journal/66/189/2/page/Issue 2: 161–162
Hulscher JB et al. (2002) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 347(21): 1662–1669
Idelevich E et al. (2012) Prospective phase II study of neoadjuvant therapy with cisplatin, 5-fluorouracil, and bevacizumab for locally advanced resectable esophageal cancer. Onkologie. 35(7–8): 427–431
Ilson DH et al. (2007) Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol. 18(5): 898–902
Ilson,DH et al. (2012) Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer. 118(11): 2820–2822
Isolauri J, Markkula H, (1989) Lye ingestion and carcinoma of the esophagus. Acta Chir Scand. 155(4–5): p. 269–71.
Jackson A et al. (2010) The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys. 76(3 Suppl): 155–160
Jemal A et al. (2011) Global cancer statistics. CA Cancer J Clin. 61(2): 69–90
Kamangar F et al. (2006) Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst. 98(20): 1445–1452
Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24(14): 2137–2150
Kato K et al. (2011) Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 81(3): 684–690
Kelsen DP et al. (2007) Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25(24): 3719–3725
Klautke G, Fietkau R, Significance of radiation therapy for adenocarcinomas of the esophagus, gastroesophageal junction and gastric cancer with special reference to the MAGIC trial. Strahlenther Onkol. 183(4): 163–169
Kleinberg L (2013) Therapy for locally advanced adenocarcinoma of the gastroesophageal junction: optimizing outcome. Semin Radiat Oncol. 23(1): 38–50
Kmet J, Mahboubi E (1972) Esophageal cancer in the Caspian littoral of Iran: initial studies. Science. 175(4024): 846–853
Kole TP et al. (2012) Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys. 83(5): 1580–1586
Kranzfelder M et al. (2011) Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg. 98(6): 768–783
Krebs in Deutschland. 8. Ausgabe. http://www.rki.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2012/krebs_in_deutschland_2012.pdf?_blob=publicationFile. zugegriffen: 14. Juni 2013
Ku GY, Ilson DH (2012) Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus. Gastrointest Cancer Res. 5(3): 85–92
Launois B et al. (1981) Preoperative radiotherapy for carcinoma of the esophagus. Surg Gynecol Obstet. 153(5): 690–692
Lee, J et al. (2012) Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 30(3): 268–723
Liao LM et al. (2012) Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology, 2012. 142(3): p. 442–452 e5; quiz e22–3
Lightdale CJ (1995) Photodynamic therapy: a new light on Barrett’s esophagus. Gastrointest Endosc. 42(1): 96–98
Lin SH et al. (2012) Propensity Score-based Comparison of Long-term Outcomes With 3-Dimensional Conformal Radiotherapy vs Intensity-Modulated Radiotherapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys
Lin SH et al. (2012) Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 83(3): e345–351
Lordick F et al. (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 8(9): 797–805
Lorenzen S et al. (2011) Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC Cancer. 11: 266
Lowe WC (1972) Survival with carcinoma of the esophagus. Ann Intern Med. 77(6): 915–918
Lutz MP et al. (2012) Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 48(16): 2941–2953
Macdonald JS et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 345(10): 725–730
Malthaner R, Wong RK, Spithoff K (2010) Preoperative or postoperative therapy for resectable oesophageal cancer: an updated practice guideline. Clin Oncol (R Coll Radiol). 22(4): 250–256
Marger RS, D. Marger D (1993) Carcinoma of the esophagus and tylosis. A lethal genetic combination. Cancer. 72(1): p.17–19
Mariette C, Piessen G (2012) Oesophageal cancer: how radical should surgery be? Eur J Surg Oncol. 38(3): 210–213
Matuschek C et al. (2011) Trimodal therapy in squamous cell carcinoma of the esophagus. Eur J Med Res. 16(10): 437–444
Matzinger O et al. (2009) EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol. 92(2): 164–175
Minsky BD et al. (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 20(5): 1167–1174
Nishihira T, Hirayama, K, Mori S, (1998) A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg. 175(1): 47–51
Nomura M et al. (2012) Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 82(2): 946–952
Nygaard K et al. (1992) Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 16(6): p. 1104–1109; discussion 1110
Offner FA (2000) Ätiologie, Molekularbiologie und Pathologie des Plattenepithelkarzinoms des Ösophagus. Der Pathologe. 21(5): 349–357
Oh DS, Demeester SR (2010) Pathophysiology and treatment of Barrett’s esophagus. World J Gastroenterol. 16(30): 3762–3772
Ojala K et al. (1982) Symptoms of carcinoma of the oesophagus. Med J Aust. 1(9): 384–385
Orlando RC (2005) Pathogenesis of reflux esophagitis and Barrett’s esophagus. Med Clin North Am. 89(2): 219–241
Overholt BF et al. (2007) Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett’s high-grade dysplasia. Gastrointest Endosc. 66(3): p. 460–468
Pasini F et al. (2012) Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase 2 study. Cancer. 119(5): 939–945
Pennathur A et al. (2013) Oesophageal carcinoma. Lancet. 381(9864): 400–412
Perez CA., Brady LW, Halperin EC, (Hrsg) (2008) Perez and Brady’s principles and practice of radiation oncology : [now in color throughout and including fully searchable online text and image bank]. 5. ed. ed. Wolters Kluwer Health. Wolters Kluwer, Lippincott Williams & Wilkins: Philadelphia, Pa. [u.a.].
Pohl H et al. (2013) Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol. 108(2): 200–207
Power DG, Ilson DH (2009) Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Ther Adv Med Oncol. 1(3): 145–165
Qumseya BJ, David W, Wolfsen HC (2013) Photodynamic Therapy for Barrett’s Esophagus and Esophageal Carcinoma. Clin Endosc. 46(1): 0–7
Rawat S et al. (2013) Chemoradiotherapy in the Management of Locally Advanced Squamous Cell Carcinoma Esophagus: Is Surgical Resection Required? J Gastrointest Cancer.
Rice TW, Blackstone EH, and Rusch VW (2010) 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 17(7): p. 1721–1724
Rice TW et al. (2010) Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 116(16): 3763–3773
Richards et al. (2013) Results of docetaxel plus oxaliplatin (DOCOX) ±cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study. European Journal of Cancer in press
Robertson R, Coy P, Mokkhavesa S (1967) The results of radical surgery compared with radical radiotherapy in the treatment of squamous carcinoma of the thoracic esophagus. The case for preoperative radiotherapy. J Thorac Cardiovasc Surg. 53(3): 430–440
Ruhstaller T et al. (2011) Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol. 29(6): 626–631
Sack H, Thesen N (1998) Bestrahlungsplanung, 2. Aufl., Thieme, Stuttgart New York.
Sadeghi S et al. (2008) Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev. 17(5): 1169–1178
Sahgal A et al. (2012) Reirradiation human spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 82(1): 107–116
Sakuramoto S et al. (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 357(18): 1810–1820
Sandler RS et al. (1995) The risk of esophageal cancer in patients with achalasia. A population-based study. JAMA. 274(17): 1359–1362
Schieman C et al. (2013) Salvage resections for recurrent or persistent cancer of the proximal esophagus after chemoradiotherapy. Ann Thorac Surg. 95(2): p. 459–463
Shaheen NJ, Spechler SJ (2008) Total endoscopic eradication of Barrett’s esophagus: study methodology, candidate selection, and clinical outcomes. Endoscopy. 40(12): 994–999
Sharma P (2009) Clinical practice. Barrett’s esophagus. N Engl J Med. 361(26): 2548–2556
Shridhar R et al. (2013) Radiation therapy and esophageal cancer. Cancer Control. 20(2): 97–110
Siewert JR et al. (2001) Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg. 234(3): 360–367; discussion 368–369
Siewert JR et al. (1987) Kardiakarzinom: Versuch einer therapeutisch relevanten Klassifikation. Chirurg. 58(1): 25–32
Siewert JR, Stein HJ, Feith M (2006) Adenocarcinoma of the esophago-gastric junction. Scand J Surg. 95(4): 260–269
Sjoquist KM et al. (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 12(7): 681–692
Smit JK et al. (2013) Survival after Definitive (Chemo)Radiotherapy in Esophageal Cancer Patients: A Population-Based Study in the North-East Netherlands. Ann Surg Oncol.Jun; 20(6): 1985–1992
Stahl M et al. (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 23(10): 2310–2317
Stahl M et al. (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 27(6): 851–856
Sterzing F, Grenacher L, Debus J (2012) Radiotherapy of gastroesophageal junction cancer. Recent Results Cancer Res. 196: 187–99
Stieler F et al. (2011) A comparison of several modulated radiotherapy techniques for head and neck cancer and dosimetric validation of VMAT. Radiother Oncol. 101(3): 388–393
Suh YS et al. (2012) Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. Ann Surg. 255(5): 908–915
Suzuki A et al. (2011) Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 117(21): 4823–4833
Saarländisches Krebsregister 2012.
Teniere P et al. (1991) Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet. 173(2): 123–130
Thrift AP et al. (2013) A model to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 11(2): p. 138–44 e2
Urba SG et al. (2001) Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 19(2): 305–313
Urschel JD, Vasan (2003), A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 185(6): 538–543
Vakil N et al. (2001) A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol. 96(6): p. 1791–1796
Vaughan.L et al. (2005) Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. Lancet Oncol. 6(12): 945–952
Vaughan TL, Kiemeney LA, McKnight B (1995) Colorectal cancer in patients with esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 4(2): 93–97
Walsh TN et al. (1996) A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 335(7): 462–467
Wang, DB et al. (2012) Neoadjuvant Chemoradiotherapy Could Improve Survival Outcomes for Esophageal Carcinoma: A Meta-Analysis. Dig Dis Sci.
Wara WM et al. (1976) Palliation for carcinoma of the esophagus. Radiology. 121(3 Pt. 1): 717–720
Weber WA et al. (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 19(12): 3058–3065
Welsh J et al. (2011) Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys. 81(5): 1336–1342
van Westreenen HL et al. (2004) Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol. 22(18): 3805–3812
Whiteman DC et al. (2010) Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology. 139(1): 73–83; quiz e11–2
Wittekind C (Hrsg) (2010) TNM-Klassifikation maligner Tumoren. 7. Aufl. Wiley-Blackwell: Weinheim. XIX, 295
Wong RK et al. (2003) Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus: a practice guideline. Int J Radiat Oncol Biol Phys. 55(4): 930–942
Wu AJ, Goodman KA (2013) Positron emission tomography imaging for gastroesophageal junction tumors. Semin Radiat Oncol. 23(1): 10–15
Yamamoto M et al. (1997) Reevaluation of postoperative radiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys. 37(1): 75–78
Huber K (2013) Überleben durch neoadjuvante Radiochemotherapie verbessert Strahlenther Onkol. 189(2): 161–162
Ychou M et al. (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 29(13): 1715–1721
Yoo C et al. (2012) Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer. Ann Thorac Surg. 94(6): 1862–1868
Yoon HH et al. (2012) Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol. 30(32): 3932–3938
Yu C et al. (2012) Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. J Cancer Res Clin Oncol. 138(2): 255–259
Zhu WG et al. (2012) A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol.
Zieren HU et al. (1995) Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg. 19(3): 444–449
Zimmermann JS, Kumpf L, Kimmig B (1998) Variability of individual normal tissue radiation sensitivity. An international empirical evaluation of endogenous and exogenous response modifiers. Strahlenther Onkol. 174 Suppl 3: 16–19
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Boda-Heggemann, J., Bürgy, D., Ronellenfitsch, U., Fritz, P., Lohr, F. (2013). Ösophaguskarzinom und Karzinom des gastroösophagealen Überganges. In: Wannenmacher, M., Wenz, F., Debus, J. (eds) Strahlentherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-88305-0_20
Download citation
DOI: https://doi.org/10.1007/978-3-540-88305-0_20
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-88304-3
Online ISBN: 978-3-540-88305-0
eBook Packages: Medicine (German Language)